Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. Hyman DM, et al. Among authors: hoffman js. Gynecol Oncol. 2017 Jan;144(1):96-100. doi: 10.1016/j.ygyno.2016.10.036. Epub 2016 Oct 27. Gynecol Oncol. 2017. PMID: 28094040 Free PMC article. Clinical Trial.
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Huh WK, et al. Among authors: hoffman js. Gynecol Oncol. 2010 May;117(2):248-54. doi: 10.1016/j.ygyno.2010.01.002. Epub 2010 Feb 26. Gynecol Oncol. 2010. PMID: 20189232 Clinical Trial.
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. Coleman RL, et al. Among authors: hoffman js. Gynecol Oncol. 2011 Jul;122(1):111-5. doi: 10.1016/j.ygyno.2011.03.036. Epub 2011 Apr 15. Gynecol Oncol. 2011. PMID: 21497382 Free PMC article. Clinical Trial.
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. Coleman RL, et al. Among authors: hoffman js. Gynecol Oncol. 2012 Dec;127(3):538-43. doi: 10.1016/j.ygyno.2012.08.020. Epub 2012 Aug 23. Gynecol Oncol. 2012. PMID: 22922531 Free PMC article. Clinical Trial.
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. Powell MA, et al. Among authors: hoffman js. Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11. Gynecol Oncol. 2014. PMID: 25019571 Free PMC article. Clinical Trial.
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM. McMeekin DS, et al. Among authors: hoffman js. Gynecol Oncol. 2015 Jul;138(1):36-40. doi: 10.1016/j.ygyno.2015.04.038. Epub 2015 May 6. Gynecol Oncol. 2015. PMID: 25958319 Free PMC article. Clinical Trial.
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. Martin LP, et al. Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18. Gynecol Oncol. 2014. PMID: 24361733 Free PMC article. Clinical Trial.
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, Buekers TE, Bell J, Schilder JM; Gynecologic Oncology Group. Fiorica JV, et al. Among authors: hoffman js. Gynecol Oncol. 2009 Nov;115(2):285-9. doi: 10.1016/j.ygyno.2009.07.024. Epub 2009 Sep 2. Gynecol Oncol. 2009. PMID: 19726073 Clinical Trial.
79 results